Cargando…

Validation of Two Rapid Diagnostic Tests for Visceral Leishmaniasis in Kenya

BACKGROUND: Visceral leishmaniasis (VL) is a systemic parasitic disease that is fatal unless treated. In Kenya, national VL guidelines rely on microscopic examination of spleen aspirate to confirm diagnosis. As this procedure is invasive, it cannot be safely implemented in peripheral health structur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mbui, Jane, Wasunna, Monique, Balasegaram, Manica, Laussermayer, Adrian, Juma, Rashid, Njenga, Simon Njoroge, Kirigi, George, Riongoita, Mark, de la Tour, Roberto, van Peteghem, Joke, Omollo, Raymond, Chappuis, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784478/ https://www.ncbi.nlm.nih.gov/pubmed/24086782 http://dx.doi.org/10.1371/journal.pntd.0002441

Ejemplares similares

Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Omollo, Raymond, et al.
Publicado: (2011)

The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis
por: Wasunna, Monique, et al.
Publicado: (2016)

Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial
por: Mbui, Jane, et al.
Publicado: (2019)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
por: Wasunna, Monique, et al.
Publicado: (2016)

Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial
por: Hailu, Asrat, et al.
Publicado: (2010)

Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme
por: Kimutai, Robert, et al.
Publicado: (2017)

Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial
por: Musa, Ahmed, et al.
Publicado: (2012)

Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study
por: Musa, Ahmed M., et al.
Publicado: (2010)

Clinical Epidemiology, Diagnosis and Treatment of Visceral Leishmaniasis in the Pokot Endemic Area of Uganda and Kenya
por: Mueller, Yolanda K., et al.
Publicado: (2014)

Single-dose liposomal amphotericin B (AmBisome(®)) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Edwards, Tansy, et al.
Publicado: (2011)

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
por: Dorlo, Thomas P C, et al.
Publicado: (2017)

Visceral leishmaniasis (kala-azar) outbreak in Somali refugees and Kenyan shepherds, Kenya.
por: Boussery, G, et al.
Publicado: (2001)

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis
por: Verrest, Luka, et al.
Publicado: (2023)

Visceral Leishmaniasis: New Health Tools Are Needed
por: Hailu, Asrat, et al.
Publicado: (2005)

Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa
por: Palić, Semra, et al.
Publicado: (2020)

Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial
por: Khalil, Eltahir A. G., et al.
Publicado: (2014)

Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent
por: Meheus, Filip, et al.
Publicado: (2010)

Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial
por: Musa, Ahmed M, et al.
Publicado: (2022)

The Economic Burden of Visceral Leishmaniasis in Sudan: An Assessment of Provider and Household Costs
por: Meheus, Filip, et al.
Publicado: (2013)

Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa
por: Verrest, Luka, et al.
Publicado: (2021)

Liposomal amphotericin B as a treatment for human leishmaniasis
por: Balasegaram, Manica, et al.
Publicado: (2012)

Characterization of visceral leishmaniasis outbreak, Marsabit County, Kenya, 2014
por: Kanyina, Evalyne Wambui
Publicado: (2020)

Visceral leishmaniasis outbreak in Kenya—a setback to the elimination efforts
por: Mewara, Abhishek, et al.
Publicado: (2022)

Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia
por: Diro, Ermias, et al.
Publicado: (2019)

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia
por: Diro, Ermias, et al.
Publicado: (2019)

Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease
por: Boelaert, Marleen, et al.
Publicado: (2014)

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis
por: Kip, Anke E., et al.
Publicado: (2018)

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
por: Rahman, Ridwanur, et al.
Publicado: (2017)

Visceral leishmaniasis
por: Sundar, Shyam
Publicado: (2015)

Innovative Approaches to Clinical Data Management in Resource Limited Settings Using Open-Source Technologies
por: Omollo, Raymond, et al.
Publicado: (2014)

A Global Comparative Evaluation of Commercial Immunochromatographic Rapid Diagnostic Tests for Visceral Leishmaniasis
por: Cunningham, Jane, et al.
Publicado: (2012)

Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study
por: Kip, Anke E, et al.
Publicado: (2021)

Congenital Visceral Leishmaniasis
por: Boehme, Catharina C., et al.
Publicado: (2006)

Immunity to Visceral Leishmaniasis
por: Ali, Nahid, et al.
Publicado: (2012)

Treatment of Visceral Leishmaniasis
por: Moore, E M, et al.
Publicado: (2010)

Immunobiology of visceral leishmaniasis
por: Kumar, Rajiv, et al.
Publicado: (2012)

Epidemiology of visceral leishmaniasis
por: Ready, Paul D
Publicado: (2014)

Risk Factors for Visceral Leishmaniasis and Asymptomatic Leishmania donovani Infection in India and Nepal
por: Picado, Albert, et al.
Publicado: (2014)

Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India
por: Goyal, Vishal, et al.
Publicado: (2018)

Treatment options for second-stage gambiense human African trypanosomiasis
por: Eperon, Gilles, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_c7msm2ikcl3t8qscjqlv3ldc9c